Latest news with #BorderlinePersonalityDisorder
Yahoo
2 days ago
- Yahoo
Mom of 3 Girls Allegedly Killed by Dad Shares Heartbreaking Video She Made for Father's Day (Exclusive)
A video exclusively shared with PEOPLE on June 6 shows a slideshow of photos of Travis Decker, Whitney Decker, and their three daughters Per police, Travis is suspected of killing the girls, Paityn Decker, 9, Evelyn Decker, 8, and Olivia Decker, 5 after their bodies were found June 2 The manhunt for Travis remains ongoing as of June 6 Before the tragic news surfaced that three girls were found dead — and their father was suspected of killing them — their mother posted an online video tribute to her now-missing ex-husband, whom she claims was a good parent despite his mental health struggles, according to her attorney. The 20-second video, shared exclusively with PEOPLE through Whitney Decker's attorney Arianna Cozart on June 6, was made as a Father's Day tribute to Travis Decker, Cozart says. The video is filled with a slideshow photos of Travis, Whitney, and their daughters, Paityn Decker, 9, Evelyn Decker, 8, and Olivia Decker, 5, while Pharrell Williams' song "Happy" plays. It's unclear when exactly the video, which has a TikTok logo, was posted online, since Whitney's account is now private. Travis is suspected of killing the girls, who were found dead on June 2 near the Rock Island Campground in Chelan County, Wash., where his pickup truck was also recovered. The sisters were reported missing on May 30 after they had not returned on time from a 'planned visitation' with Travis, according to police. "Travis was a present and active father up until the end — still attending the girls' soccer games, dance, and theater productions," Cozart said in an emailed statement to PEOPLE on June 6. "Although Travis was struggling with his own mental health, he was a good co-parent, always communicating frequently with Whitney up until Friday evening when the girls went missing." According to Cozart, Decker and Whitney were married for a little over seven years and "his mental health struggles, including his feelings of isolation, paranoia, and Borderline Personality Disorder led to the crumbling of their marriage in 2022." The attorney notes that Travis, who was an Army veteran, was seeking mental health care but was unable to obtain it. Whitney later sought limitations to his parenting time, as explained in a September 2024 parenting plan filed in Chelan County Superior Court and viewed by PEOPLE. She claimed in a separate filing, also viewed by PEOPLE, that Decker had "neglected his parental duties towards a child" and "has a long-term emotional or physical problem that gets in the way of his ability to parent." He'd been granted visitations to visit his daughters for three hours on Fridays and eight hours every other weekend, as long as he stayed in Wenatchee Valley, per the parenting plan filing. He was not granted overnight visits. The schedule was only temporary due to the court process, Cozart says. In the filing, Whitney also asked that Decker be evaluated for anger management/domestic violence, and have a full psychiatric evaluation by a licensed psychiatrist to include any potential diagnoses. The filing stated that if Decker didn't follow through with these things, the "mother will have the choice to further limit visitation." Want to keep up with the latest crime coverage? Sign up for for breaking crime news, ongoing trial coverage and details of intriguing unsolved cases. Cozart tells PEOPLE that Travis "was not a violent man with Whitney or the girls, ever." The manhunt remains ongoing for Travis who is currently wanted for three counts of first-degree murder and one count of kidnapping, on top of custodial interference charges. The Chelan County Sheriff's Office previously said in Facebook post that Decker is "well versed in wilderness survival and capable of spending days or even weeks in the wilderness on his own and with very little equipment." Authorities are asking anyone who has seen Travis to call 911 immediately and do not attempt to approach him. People can also call the CCSO tip line at 509-667-6845 or submit information to the tip line. If you or someone you know needs mental health help, text "STRENGTH" to the Crisis Text Line at 741-741 to be connected to a certified crisis counselor. Read the original article on People
Cision Canada
6 days ago
- Health
- Cision Canada
Homewood Health Centre's 3rd Annual Mental Health Symposium Highlights Women's Leadership in Mental Health Care
Over 190 primary care providers from across Canada including family and specialist physicians, nurse practitioners, physician assistants, and social workers attended the event in-person and virtually. In her welcome remarks, Jagoda Pike, CEO of Homewood Health Centre and President and CEO, Homewood Health Inc., emphasized the essential role of primary care providers in shaping mental health outcomes: "With the increased prevalence of mental health disorders nationally, enhancing mental health education in primary care practice is ever more critical. As frontline health care providers, they are uniquely positioned to identify early signs of illness and facilitate intervention. We want to empower them to make informed decisions while challenging and changing perceptions about accessing care." Driving Progress in Women's Mental Health The extensive knowledge and diverse perspectives shared by an all-female identifying panel aligned with Homewood Health Centre's initiatives to advance women's mental health outcomes. These include a collaboration with Dr. Benicio Frey, the inaugural Homewood Research Chair in Women's Mental Health and Depression, to translate research into clinical practice, and the launch of the Women's Trauma and Concurrent Program at Homewood Health Centre - one of the first of its kind in Canada, dedicated to treating complex trauma in women. "We aim to create more avenues to highlight women's invaluable contributions in this field—their insights will inspire change in health care," said CEO Pike. The panel of distinguished clinical experts delivered peer-reviewed research on several topics: Underexplored aspects of post-traumatic stress disorder - Dr. Margaret McKinnon Harnessing the mind-body connection in the treatment of chronic pain - Dr. Jaclyn Kukat & Dr. Rhonda Taylor Beyond the label: Understanding Borderline Personality Disorder to help facilitate management in Primary Care - Dr. Naomi Mudachi Cycles of Care: Navigating Mental Health Through Pregnancy, Postpartum, and Beyond - Dr. Lisa Gagnon Mindful Moments: Cultivating Inner Peace in Mental Health - Dr. Tara Riddell Bipolar Disorder in Primary Care: What to Do When Specialty Care Isn't Available - Dr. Zainab Mohamed Spotlight on Mental Health Struggles in Women's Elite Sports Women's rugby athlete and mental health advocate Brianna Martey also delivered an insightful presentation titled "Mental Health Struggles in the High-Performance Athlete." Drawing from lived experience, she courageously shared the complexities of balancing her mental well-being with the rigorous demands of elite sports. Event moderator Dr. Carlos Lalonde, President and Chief of Staff of Homewood Health Centre, reaffirmed Homewood's commitment to transforming lives and expanding its impact through research, partnerships, and education. "Empowering change in our health care system relies on education and enhanced collaborations. Through our shared focus, we can create an unparalleled healing force for patients, families and communities across Canada." The Mental Health Symposium was a free, fully accredited event and certified by the College of Family Physicians of Canada and the Ontario Chapter. About Homewood Health With over 140 years of experience, Homewood Health is at the forefront of mental health and well-being, providing Canadians with an unparalleled continuum of care. We achieve outstanding outcomes every day through our national network of over 4,500 employees and clinical experts working in partnership with leading employers, organizations and researchers. Our unique and comprehensive stepped care continuum provides the most complete range of mental health services available nationally – from organizational support & training programs to employee assistance & mental health programs, as well as specialized expertise in assessments, return to work, recovery management and family support – all supported by our medical and mental health expertise in our nationally recognized treatment facilities: Homewood Health Centre, Homewood Ravensview and The Residence at Homewood.
Daily Mirror
13-05-2025
- Entertainment
- Daily Mirror
‘I've been in therapy for years - here's 13 reasons why you need it'
Emma and Matt Willis have long reaped the benefits of the therapist's office. Now, they're bringing that same healing to the small screen in their new BBC One show. After wrapping Love Is Blind UK, the pair return in Change Your Mind, Change Your Life - a four-part series hosted by Emma Willis and her hubby, former Busted star Matt Willis, alongside four of Britain's top-rated therapists. It's packed with raw moments and real tools. The show's participants confront every demon - grief, anxiety, self-doubt - as they step into their healing journey. No dazzling lights, no filters, just the messy, brave work of getting better. The new series champions therapy as a tool for transformation. And as someone who's seen eight therapists in twenty years, I can confirm: therapy isn't just helpful - it's life-saving. Here's why. We check in with GPs when our bodies feel off - why not do the same for our minds? These days, I see my therapist after tough days or overstimulating city trips. It's routine care for my mental health and just as necessary. Talking helps, but therapy goes further. It gives you frameworks. Strategies. My current therapist had me create a trauma timeline and even assigned reading - because healing requires structure, not just venting. I was misdiagnosed with Borderline Personality Disorder (BPD) by a specialist who'd only seen me once. My current therapist, Jamie, worked with me consistently, challenging that label and eventually helping me get properly diagnosed with C-PTSD and high-functioning autism. BPD came with a mountain of stigma. People treated me like I was dangerous or manipulative. Therapy helped me unlearn the shame and advocate for a rediagnosis that finally made sense. I was abused in every way a child can be. That left deep wounds - and deeper confusion. Therapy helped me name what happened, and finally separate my identity from my trauma. As a teen, I was emotionally explosive. I lashed out at everyone - parents, teachers, friends. Therapy taught me how to regulate my emotions rather than drown in them. Before therapy, I couldn't hold down friendships or romantic connections. Intimacy was terrifying. Now, my relationships are grounded, honest and drama-free. (Well, mostly.) I used to think saying 'no' meant I was mean. Now, I know that boundaries are kindness in disguise - and therapy helped me find the language and courage to set them. I used to fall apart after every breakup. Therapy gave me coping strategies, self-soothing tools, and perspective. Now, I survive endings without losing myself. My trauma taught me I deserved pain. Therapy taught me I didn't. That I am not what happened to me. That I am allowed peace and softness. Even love. Under the wrong label, I was medicated into numbness - Xanax, escitalopram, even antipsychotics. Therapy helped me find what actually worked: a low dose of sertraline, some mediation and a lot less shame. You don't need to be in crisis to benefit from therapy. These days, I attend semi-regularly, even during the good times. It keeps me grounded and self-aware. Quite literally. I checked myself into a psych hospital at 19, desperate for help. Without therapy, I wouldn't be here - not as myself anyway. Therapy gave me back my life. And if it's made me 'crazy,' I'll take crazy over numb any day.
Yahoo
19-03-2025
- Business
- Yahoo
High Growth Tech Stocks In Europe March 2025
In March 2025, the European market is navigating a complex landscape characterized by concerns over U.S. trade tariffs, economic growth uncertainties, and fluctuating monetary policies. Despite these challenges, high growth tech stocks in Europe continue to attract attention as investors seek opportunities that align with resilient business models and innovative capabilities capable of weathering broader market volatility. Name Revenue Growth Earnings Growth Growth Rating Elicera Therapeutics 63.53% 97.24% ★★★★★★ Pharma Mar 24.24% 40.82% ★★★★★★ CD Projekt 30.55% 39.06% ★★★★★★ Yubico 20.88% 26.53% ★★★★★★ Xbrane Biopharma 73.73% 139.21% ★★★★★★ XTPL 97.45% 117.95% ★★★★★★ Devyser Diagnostics 26.50% 94.65% ★★★★★★ Elliptic Laboratories 49.76% 88.21% ★★★★★★ Ascelia Pharma 46.09% 66.93% ★★★★★★ Skolon 29.71% 91.18% ★★★★★★ Click here to see the full list of 243 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €228.43 million. Operations: Oryzon Genomics focuses on the discovery and development of epigenetics-based therapeutics targeting cancer and CNS disorders. As a clinical stage biopharmaceutical company, it does not currently report revenue from product sales. Oryzon Genomics is making significant strides in the biotech sector, particularly in precision medicine for psychiatric and neurodevelopmental disorders. Recently, Oryzon announced positive outcomes from Phase IIa trials of vafidemstat in various psychiatric conditions and is advancing this promising drug into a Phase III trial for Borderline Personality Disorder, with FDA discussions set for the first half of 2025. This progression underscores Oryzon's commitment to addressing unmet medical needs through innovative therapies. Furthermore, the company's recent presentation at BIO-Europe Spring and its continuous R&D efforts highlight its potential to impact future treatments significantly. With an annual revenue growth forecast at 52% and earnings expected to surge by approximately 54%, Oryzon exemplifies a dynamic player within Europe's high-growth tech landscape. Navigate through the intricacies of Oryzon Genomics with our comprehensive health report here. Gain insights into Oryzon Genomics' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: BioGaia AB (publ) is a healthcare company that develops and sells probiotic products globally, with a market capitalization of SEK11.83 billion. Operations: The company generates revenue primarily from its Pediatrics segment, contributing SEK 1.09 billion, followed by the Adult Health segment at SEK 321.29 million. BioGaia, a Swedish biotech firm, has recently demonstrated robust financial performance with its Q4 sales surging by 23% to SEK 365 million and operating profit increasing by 28% to SEK 103 million. This growth is underpinned by an annual revenue increase of 10.9% and earnings growth forecasted at 15% per year, outpacing the Swedish market averages significantly. The company's strategic move to directly manage its operations in France reflects a proactive approach in tapping into the growing health-conscious consumer base there, leveraging its reputation for high-quality probiotics. These developments suggest BioGaia is effectively capitalizing on niche market trends while maintaining strong financial health. Click here to discover the nuances of BioGaia with our detailed analytical health report. Assess BioGaia's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Telefonaktiebolaget LM Ericsson (publ) is a company that offers mobile connectivity solutions to communications service providers, enterprises, and the public sector, with a market capitalization of approximately SEK278.13 billion. Operations: Ericsson generates revenue primarily from its Networks segment, which accounts for SEK158.21 billion, followed by Cloud Software and Services at SEK62.64 billion, and Enterprise at SEK24.86 billion. The company's business model focuses on providing mobile connectivity solutions to various sectors including communications service providers and enterprises. Telefonaktiebolaget LM Ericsson, a stalwart in telecommunications, is making significant strides in leveraging advanced technologies like AI and 5G. With its recent strategic alliances, including a notable partnership with Volvo Group and Bharti Airtel to explore Extended Reality and Digital Twin technologies, Ericsson is at the forefront of industrial digital transformation. This collaboration aims to enhance manufacturing processes and workforce training through the integration of 5G's ultra-low latency capabilities. Financially, Ericsson has demonstrated robust growth with a notable increase in earnings forecasted at an impressive 47% annually. Despite moderate revenue growth projections at 1.9% per year, the company's commitment to R&D remains strong, ensuring sustained innovation and competitiveness in the high-tech industry landscape. Dive into the specifics of Telefonaktiebolaget LM Ericsson here with our thorough health report. Review our historical performance report to gain insights into Telefonaktiebolaget LM Ericsson's's past performance. Click here to access our complete index of 243 European High Growth Tech and AI Stocks. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:ORY OM:BIOG B and OM:ERIC B. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
03-03-2025
- Business
- Yahoo
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
Leading US psychiatric experts join Oryzon's Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and key secondary endpoints for Phase III trial, aligned with FDA standards Oryzon moves forward with plans to submit Phase III protocol to the FDA in 1H 2025 MADRID and CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has established the primary and key secondary endpoints for its planned Phase III clinical trial evaluating vafidemstat in Borderline Personality Disorder (BPD). This milestone was reached in collaboration with Oryzon's newly formed Clinical Advisory Board (CAB), composed of leading experts in psychiatry research and clinical trials for psychiatric disorders. The CAB's insights have been instrumental in ensuring that the Phase III protocol aligns with FDA expectations and incorporates well-validated, widely recognized assessment scales to measure agitation and aggression in BPD patients. This development follows the successful completion of the Phase IIb PORTICO trial, which received positive feedback from the FDA, and positions Oryzon to submit the Phase III protocol for regulatory review in the first half of 2025. 'We are honored to collaborate with such a distinguished panel of experts as we advance vafidemstat into Phase III development,' said Dr. Carlos Buesa, Chief Executive Officer of Oryzon. 'Their expertise in psychiatric disorders and clinical trial methodology strengthens our program and ensures that we are well-prepared for the next regulatory interactions. Addressing aggression and agitation in BPD remains an urgent medical need, and we are committed to delivering innovative solutions for these patients.' Oryzon's Clinical Advisory Board Members: Oryzon's CAB includes internationally recognized leaders in psychiatry and clinical trial research: Dr. Alan F. Schatzberg, Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences at , former Chair of the Department (1991–2010), and current Director of the Stanford Mood Disorders Center. A past President of the American Psychiatric Association (2009–2010), he is a leading expert in mood disorders, particularly the neurobiology and treatment of depression. Dr. Eric Hollander, Professor of Psychiatry and Director of the Autism and Obsessive Compulsive Spectrum Program at , is a leading authority on obsessive-compulsive and related disorders. He has received multiple NIMH grants to develop treatments for BPD, with a research focus on the neurobiology of aggression and affective instability in BPD. Dr. Sarah Fineberg, Assistant Professor of Psychiatry at , specializes in the neurobiology of BPD. Her research explores social cognition and decision-making using computational psychiatry and neuroimaging. She has led clinical trials testing novel interventions for BPD, including sub-anesthetic ketamine for BPD and real-time fMRI neurofeedback. Dr. Emil F. Coccaro, George T. Harding III, M.D., Endowed Professor in the Department of Psychiatry and Behavioral Health at , is a leading expert in the neurobiology of aggression and impulsivity. His work has significantly advanced the understanding and treatment of impulsive aggression in BPD through pharmacological interventions. 'These are the right experts to help us shape a Phase III program that is both scientifically rigorous and clinically meaningful,' added Dr. Buesa. 'It is particularly reassuring that their expert medical opinion and years of practice recognize aggression as one of the most debilitating aspects of many psychiatric disorders, and particularly in borderline personality disorder. Their contributions have been instrumental in defining the primary and secondary endpoints, that will generate robust data for regulatory submissions.' Next Steps in Vafidemstat's Development Oryzon remains committed to progressing vafidemstat as a potential first-in-class treatment for agitation and aggression in BPD. Following the FDA's feedback on the PORTICO trial results, Oryzon plans to submit the Phase III protocol in the first half of 2025, with trial initiation expected soon after, pending regulatory approval and securing the necessary funding. Beyond BPD, vafidemstat is being evaluated in a Phase IIb trial for the treatment of negative symptoms in schizophrenia (EVOLUTION trial) and is part of Oryzon's broader CNS precision medicine approach. The company is also exploring additional applications in genetically defined subpopulations and neurodevelopmental disorders. For more information about the experience of the CAB members, please visit the CAB section in our website, here. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit About Vafidemstat Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer's disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong, and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed two Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders (REIMAGINE, see Ferrer et al, Psychiatry & Clin Neurosci, 2025, and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive clinical results reported in both. Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL trial in patients with Mild to Moderate AD, where a significant reduction of the inflammatory biomarker YKL40 was observed after 6 and 12 months of treatment, and the pilot, small-scale SATEEN trial in Relapse-Remitting and Secondary Progressive MS, where anti-inflammatory activity was also observed. Vafidemstat has also been tested in a Phase II in severe Covid-19 patients (ESCAPE) assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection, where it showed significant anti-inflammatory effects in severe Covid-19 patients. Vafidemstat is currently advancing as a Phase III-ready asset in Borderline Personality disorder (BPD) following completion of the global, randomized, double blind Phase IIb PORTICO trial (final data presented at ECNP-2024). Following receipt of the minutes from the End-of-Phase II meeting with the FDA to discuss PORTICO's results, the company announced plans to move forward with a Phase III PORTICO-2 trial in agitation/aggression in BPD (FDA submission planned in 1H2025). Vafidemstat is also being investigated in a double-blind, randomized, placebo-controlled Phase IIb trial in negative symptoms of schizophrenia (EVOLUTION trial, recruitment ongoing). The company is also deploying a CNS precision medicine approach with vafidemstat in genetically-defined patient subpopulations of certain CNS disorders and is evaluating a clinical trial in Kabuki Syndrome patients. The company is also exploring the clinical development of vafidemstat in other neurodevelopmental syndromes. FORWARD-LOOKING STATEMENTSThis communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration. Spain Oryzon IR & Media, Europe & US Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid Atrevia Chief BD Officer LifeSci Advisors, LLC +34 91 564 07 25 +34 673 33 97 65 +34 93 515 1313 +41 78 680 05 38 pcobo@ mcordera@ etorrell@ svonderweid@ Sign in to access your portfolio
